Merck KGaA Appeals Erbitux Rejection for Lung Cancer
July 31st, 2009
Merck KGaA said it has asked European regulators to reconsider their rejection of its top- selling cancer drug Erbitux for lung cancer patients.
The drugmaker is open to restricting which lung cancer patients are recommended to take Erbitux and doesn’t plan additional clinical tests to support its appeal, said Gangolf Schrimpf, a spokesman for the Darmstadt, Germany-based company.